Concerns Over FDA's Handling of Puberty Blockers Safety Issues

None of the 70,000 Adverse Events of Puberty Blocking Drugs Were a “Safety Priority” for Biden’s FDA ⋆ Brownstone Institute 🔗

Trump’s executive order to Protecting Children From Chemical And Surgical Mutilation is step, but FDA leadership should have been concerned.

Concerns have arisen regarding the FDA's handling of safety issues related to puberty blockers and cross-sex hormones, particularly in children. Over the past two decades, around 70,000 adverse event reports concerning these drugs have been submitted to the FDA, yet they remain unaddressed in the agency's safety reports. The Drug Risk Management Board (DRMB), which has replaced the Safety First Steering Committee, has been criticized for not prioritizing these safety concerns. Under former chairwoman Dr. Patrizia Cavazzoni, there have been allegations of political bias influencing drug safety decisions, with a lack of public awareness about the potential dangers associated with these medications. Comparatively, the FDA has been more proactive in warning about the risks of certain other drugs, raising questions about its priorities and transparency.

The FDA has received 70,000 reports of harm from puberty blockers, none of which were prioritized.
The DRMB has replaced the Safety First Steering Committee but lacks public transparency.
Dr. Patrizia Cavazzoni faced criticism for her handling of drug safety and political influences during her tenure.

What is the main concern regarding puberty blockers mentioned in the text?

There are significant safety concerns surrounding puberty blockers, particularly their use in children, with thousands of adverse event reports overlooked by the FDA.

Who was the chairwoman of the Drug Risk Management Board (DRMB)?

Dr. Patrizia Cavazzoni was the chairwoman of the DRMB and has been criticized for not prioritizing drug safety issues related to puberty blockers.

How does the FDA's response to puberty blockers compare to other drugs?

The FDA has been more active in warning about the risks of drugs like hydroxychloroquine, despite far fewer adverse reports, suggesting a discrepancy in how it addresses safety concerns.